[1]
Frank GJ, Knapp LE, McLain RW. Overall tolerance and safety of quinapril in clinical trials. Angiology. 1989 Apr:40(4 Pt 2):405-15
[PubMed PMID: 2650583]
[2]
Sedman AJ, Posvar E. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure. Angiology. 1989 Apr:40(4 Pt 2):360-9
[PubMed PMID: 2539762]
[3]
Maclean D. Quinapril: a double-blind, placebo-controlled trial in essential hypertension. Angiology. 1989 Apr:40(4 Pt 2):370-81
[PubMed PMID: 2650581]
Level 1 (high-level) evidence
[4]
Begg EJ, Robson RA, Bailey RR, Lynn KL, Frank GJ, Olson SC. The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment. British journal of clinical pharmacology. 1990 Aug:30(2):213-20
[PubMed PMID: 2144994]
[5]
. Drugs for chronic heart failure. The Medical letter on drugs and therapeutics. 2021 Jun 14:63(1626):89-96
[PubMed PMID: 34181628]
Level 3 (low-level) evidence
[6]
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022 May 3:79(17):e263-e421. doi: 10.1016/j.jacc.2021.12.012. Epub 2022 Apr 1
[PubMed PMID: 35379503]
Level 1 (high-level) evidence
[7]
Dominguez LJ, Barbagallo M, Kattah W, Garcia D, Sowers JR. Quinapril reduces microalbuminuria in essential hypertensive and in diabetic hypertensive subjects. American journal of hypertension. 1995 Aug:8(8):808-14
[PubMed PMID: 7576397]
[8]
Raia JJ Jr, Barone JA, Byerly WG, Lacy CR. Angiotensin-converting enzyme inhibitors: a comparative review. DICP : the annals of pharmacotherapy. 1990 May:24(5):506-25
[PubMed PMID: 2188439]
Level 2 (mid-level) evidence
[9]
Squire IB, Macfadyen RJ, Lees KR, Hillis WS, Reid JL. Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure. British journal of clinical pharmacology. 1994 Aug:38(2):117-23
[PubMed PMID: 7981011]
[10]
Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). Journal of the American College of Cardiology. 2000 Jan:35(1):60-6
[PubMed PMID: 10636260]
Level 2 (mid-level) evidence
[11]
Marinescu MA, Löffler AI, Ouellette M, Smith L, Kramer CM, Bourque JM. Coronary microvascular dysfunction, microvascular angina, and treatment strategies. JACC. Cardiovascular imaging. 2015 Feb:8(2):210-20. doi: 10.1016/j.jcmg.2014.12.008. Epub
[PubMed PMID: 25677893]
[12]
Kaplan HR, Taylor DG, Olson SC, Andrews LK. Quinapril--a preclinical review of the pharmacology, pharmacokinetics, and toxicology. Angiology. 1989 Apr:40(4 Pt 2):335-50
[PubMed PMID: 2539761]
[13]
Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application., Kieback AG,Felix SB,Reffelmann T,, Expert opinion on drug metabolism & toxicology, 2009 Oct
[PubMed PMID: 19761414]
Level 3 (low-level) evidence
[14]
Miller MA, Texter M, Gmerek A, Robbins J, Shurzinske L, Canter D. Quinapril hydrochloride effects on renal function in patients with renal dysfunction and hypertension: a drug-withdrawal study. Cardiovascular drugs and therapy. 1994 Apr:8(2):271-5
[PubMed PMID: 7918140]
[15]
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022 May 3:79(17):1757-1780. doi: 10.1016/j.jacc.2021.12.011. Epub 2022 Apr 1
[PubMed PMID: 35379504]
Level 1 (high-level) evidence
[16]
Pucci M, Sarween N, Knox E, Lipkin G, Martin U. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits. Expert review of clinical pharmacology. 2015 Mar:8(2):221-31. doi: 10.1586/17512433.2015.1005074. Epub 2015 Jan 22
[PubMed PMID: 25612630]
[17]
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstetrics and gynecology. 2019 Jan:133(1):e26-e50. doi: 10.1097/AOG.0000000000003020. Epub
[PubMed PMID: 30575676]
[20]
Canter D, Frank GJ, Knapp LE, McLain RW. The safety profile of quinapril: is there a difference among ACE inhibitors? Clinical cardiology. 1990 Jun:13(6 Suppl 7):VII39-42
[PubMed PMID: 2189620]
[21]
Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. The Annals of pharmacotherapy. 1996 Jan:30(1):55-61
[PubMed PMID: 8773167]
[22]
Palmquist S, Mathews B. Isolated intestinal type angioedema due to ACE-inhibitor therapy. Clinical case reports. 2017 May:5(5):707-710. doi: 10.1002/ccr3.925. Epub 2017 Mar 31
[PubMed PMID: 28469880]
Level 3 (low-level) evidence
[23]
Bharate SS. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities. Journal of medicinal chemistry. 2021 Mar 25:64(6):2923-2936. doi: 10.1021/acs.jmedchem.0c02120. Epub 2021 Mar 11
[PubMed PMID: 33706513]
[24]
Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation. 2016 Mar 15:133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622. Epub
[PubMed PMID: 26976916]
[25]
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019 Sep 10:74(10):e177-e232. doi: 10.1016/j.jacc.2019.03.010. Epub 2019 Mar 17
[PubMed PMID: 30894318]
Level 1 (high-level) evidence
[26]
Stubblefield WB, Jenkins CA, Liu D, Storrow AB, Spertus JA, Pang PS, Levy PD, Butler J, Chang AM, Char D, Diercks DB, Fermann GJ, Han JH, Hiestand BC, Hogan CJ, Khan Y, Lee S, Lindenfeld JM, McNaughton CD, Miller K, Peacock WF, Schrock JW, Self WH, Singer AJ, Sterling SA, Collins SP. Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department. Circulation. Cardiovascular quality and outcomes. 2021 Oct:14(10):e007956. doi: 10.1161/CIRCOUTCOMES.121.007956. Epub 2021 Sep 24
[PubMed PMID: 34555929]
Level 2 (mid-level) evidence
[27]
Lucas C, Christie GA, Waring WS. Rapid onset of haemodynamic effects after angiotensin converting enzyme-inhibitor overdose: implications for initial patient triage. Emergency medicine journal : EMJ. 2006 Nov:23(11):854-7
[PubMed PMID: 17057137]
[28]
Van Reet B, Dens J. Auto-intoxication with flecainide and quinapril: ECG-changes, symptoms and treatment. Acta cardiologica. 2006 Dec:61(6):669-72
[PubMed PMID: 17205927]